Legal Intern (2027)

About the role

The Indiana Biosciences Research Institute (IBRI) is seeking a student interested in law, compliance, public policy, or life sciences for a Legal Intern position. The intern will support research-related legal and compliance work in a professional, mission-driven environment.

Program Dates: May 17, 2027 – August 6, 2027
Application Deadline: Applications will be accepted through November 30, 2026. For priority consideration, apply by October 15, 2026.

Schedule

35 hours per week

Pay

Stipend of $9,650, disbursed in bi-weekly installments on or before the 7th and 22nd of each month.

Responsibilities

• Conduct basic legal and regulatory research and summarize findings.
• Help organize and track research-related agreements, such as NDAs and collaboration agreements.
• Support compliance documentation, records, and internal reviews.
• Prepare meeting materials, legal files, and project notes.
• Learn about legal topics related to research partnerships, intellectual property, and institutional policies.
• Learn how legal and compliance teams support biomedical research, partnerships, and responsible operations.

Requirements

• Enrolled in (or recently graduated from) an Indiana university undergraduate and/or graduate program, OR having graduated from an Indiana High School.
• Degree in pre-law, legal studies, public policy, biology, chemistry, biotechnology, or a related field; or a law student with interest in life sciences.
• Interest in law as it relates to biomedical research, healthcare, or regulated scientific environments.
• Strong written and verbal communication skills, with the ability to summarize information clearly.
• Basic research and analytical skills; willingness to learn legal and regulatory concepts.
• Attention to detail and strong organizational skills.
• Ability to handle confidential and sensitive information with professionalism.
• Proficiency with Microsoft Office (Word, Excel, Outlook); willingness to learn document management systems.
• Ability to work independently while collaborating with legal, compliance, and research staff.

About the organization

The Indiana Biosciences Research Institute (IBRI) is a first-in-class translational medicine institute dedicated to advancing life sciences in the race to eliminate disease and improve human health and life. By connecting early-stage biotech companies with cutting-edge life science discoveries — and backed by the mission and resources of industry leaders, investors, and philanthropic partners — IBRI is evolving a new, independent model to conquer disease, uniting previously fragmented forces in the quest for cures.

IBRI carefully curates and supports early-stage companies with investment, talent, and space, strategically accelerating drug discovery. Its relatively low cost of living and doing business allows more resources to be directed toward science. Fueled by entrepreneurial creativity, IBRI's labs advance research across the frontiers of diabetes, metabolic disease, Alzheimer's disease, and rare pediatric diseases. Its ambitious public–private vision cultivates talent while efficiently bridging the gap between research-driven inquiry and profit-driven drug development.

At IBRI, cures are launched on a clear pathway to clinical trials, enabled by the combined resources and experience of academic and industry partners, without the typical pressure to deliver rapid results for commercialization. IBRI labs pursue breakthroughs that might never happen elsewhere.

The institute's novel financing model ensures that when discoveries are ready for clinical trials, the intellectual property is sold back to industry or spun off, creating a direct stream of revenue. By every measure, the IBRI model delivers rewards: scientific bench work is nurtured, drug discovery is advanced, workforce development is continuous, investors see returns, and donors see impact. Most importantly, IBRI's structure and portfolio of accomplishments matter to the patients whose lives are improved — or even saved — by this forward-looking approach to life sciences. IBRI is driven to bring next-generation therapies to market with an understanding of the complex pressures that often bind innovation to economics. After more than a decade, the evidence is clear: IBRI is poised to transform life sciences — and for millions of people, even life itself.